|
Forecast
Period
|
2025-2029
|
|
Market
Size (2023)
|
USD
557.67 Million
|
|
CAGR
(2024-2029)
|
5.81%
|
|
Fastest
Growing Segment
|
Upper
GI Tract
|
|
Largest
Market
|
North
America
|
|
Market
Size (2029)
|
USD
771.84 Million
|
Market Overview
Global
Gastrointestinal Bleeding Treatment Market was valued at USD 557.67 million in
2023 and are expected to achieve an steady growth in the forecast period at a CAGR of 5.81%
through 2029. Gastrointestinal bleeding treatment refers to the management and
intervention strategies employed to address bleeding that occurs within the
digestive tract, which includes the esophagus, stomach, small intestine, large
intestine (colon), rectum, and anus. Gastrointestinal bleeding can manifest as
either upper gastrointestinal bleeding (UGIB), which originates from the upper
part of the digestive system, or lower gastrointestinal bleeding (LGIB), which
originates from the lower part of the digestive system. Patients presenting
with acute gastrointestinal bleeding may require immediate resuscitation and
stabilization to address hemodynamic instability, restore fluid and electrolyte
balance, and optimize oxygenation and tissue perfusion.
Diagnostic tests such
as upper endoscopy, colonoscopy, capsule endoscopy, and imaging studies (e.g.,
CT angiography, nuclear medicine scans) are performed to identify the source,
location, and severity of gastrointestinal bleeding and guide subsequent
treatment decisions. Pharmacological interventions may be utilized to manage
gastrointestinal bleeding, including the administration of proton pump
inhibitors (PPIs) to reduce gastric acid secretion, antibiotics to eradicate
Helicobacter pylori infection, vasoactive drugs to control bleeding, and
hemostatic agents to promote clot formation and hemostasis. Endoscopic
procedures, such as thermal coagulation, injection sclerotherapy, band
ligation, hemostatic clip application, and argon plasma coagulation, may be
performed to achieve hemostasis and control bleeding from ulcers, varices,
arteriovenous malformations (AVMs), and other lesions within the gastrointestinal
tract.
The
increasing prevalence of gastrointestinal disorders such as peptic ulcers,
inflammatory bowel disease (IBD), colorectal cancer, diverticular disease, and
vascular abnormalities contributes to the demand for gastrointestinal bleeding
treatment. As the incidence of these conditions rises globally, the need for
effective treatment options for gastrointestinal bleeding also increases. Advances
in medical technology, particularly in endoscopic imaging, interventional
radiology, and surgical techniques, have expanded the treatment options
available for gastrointestinal bleeding. New technologies enable healthcare
providers to diagnose and treat gastrointestinal bleeding more accurately and
effectively, improving patient outcomes and reducing the risk of complications.
Increased awareness of gastrointestinal disorders and the importance of early
detection and treatment has led to the implementation of screening programs for
conditions such as colorectal cancer. Screening programs help identify
individuals at risk of gastrointestinal bleeding and enable early intervention,
improving patient outcomes and reducing healthcare costs associated with
advanced disease stages.
Key Market Drivers
Rising Prevalence of
Gastrointestinal Disorders
Peptic
ulcers are open sores that develop on the lining of the stomach, small
intestine, or esophagus. They can result from infection with Helicobacter
pylori bacteria, long-term use of nonsteroidal anti-inflammatory drugs
(NSAIDs), excessive alcohol consumption, and smoking. Peptic ulcers can cause
bleeding, leading to gastrointestinal bleeding. Inflammatory bowel disease
comprises conditions such as Crohn's disease and ulcerative colitis, which
involve chronic inflammation of the digestive tract. Inflammatory bowel disease
can lead to ulcers, fissures, and inflammation throughout the gastrointestinal
tract, increasing the risk of gastrointestinal bleeding. Colorectal cancer
refers to cancer that develops in the colon or rectum. It is one of the leading
causes of cancer-related deaths worldwide. Colorectal cancer can cause bleeding
from tumors or ulcerated areas within the colon or rectum, resulting in gastrointestinal
bleeding.
Diverticular
disease involves the formation of small pouches (diverticula) in the colon.
Diverticulosis refers to the presence of diverticula without inflammation,
while diverticulitis occurs when diverticula become inflamed or infected. In
severe cases, diverticulitis can cause bleeding and lead to gastrointestinal
bleeding. Abnormalities in blood vessels within the gastrointestinal tract,
such as arteriovenous malformations (AVMs) and angiodysplasia, can predispose
individuals to gastrointestinal bleeding. These vascular malformations may
rupture or bleed spontaneously, leading to acute or chronic gastrointestinal
bleeding. Gastritis refers to inflammation of the stomach lining, while
esophagitis involves inflammation of the esophagus. Chronic gastritis and
esophagitis can result from various factors, including infection with
Helicobacter pylori, excessive alcohol consumption, and gastroesophageal reflux
disease (GERD). Inflammation and erosion of the gastrointestinal mucosa in
gastritis and esophagitis can lead to bleeding. This factor will help in the
development of the Global Gastrointestinal Bleeding Treatment Market.
Increasing Awareness and
Screening Programs
Awareness
and screening programs increase public awareness of gastrointestinal disorders,
their risk factors, and associated symptoms. By educating individuals about the
signs and symptoms of gastrointestinal conditions such as colorectal cancer,
inflammatory bowel disease (IBD), and peptic ulcers, these programs encourage
early recognition of potential gastrointestinal bleeding and prompt individuals
to seek medical evaluation and treatment. Awareness campaigns help reduce
stigma associated with gastrointestinal symptoms and encourage individuals to
overcome barriers to seeking medical care. By raising awareness about the
importance of gastrointestinal health and promoting open discussions about
digestive symptoms, these programs empower individuals to prioritize their
health and seek timely medical attention for gastrointestinal bleeding and
related concerns. Awareness and screening programs promote evidence-based
screening guidelines for gastrointestinal disorders, such as colorectal cancer
screening guidelines endorsed by medical societies and public health
organizations. By disseminating information about recommended screening
modalities, age-based screening recommendations, and risk factors for
gastrointestinal bleeding, these programs encourage individuals to undergo
appropriate screening tests and preventive measures to detect gastrointestinal
disorders at an early stage.
Awareness
and screening programs facilitate access to screening services by raising
awareness about available screening options, facilitating referrals to
healthcare providers, and providing information about screening locations and
resources. By increasing access to screening services, particularly in
underserved communities and populations with limited healthcare access, these
programs help identify individuals at risk of gastrointestinal bleeding and
facilitate timely referral for diagnostic evaluation and treatment. Awareness
and screening programs empower patients to actively participate in their
healthcare decisions and engage in preventive health behaviors. By promoting
shared decision-making between patients and healthcare providers, these
programs facilitate informed discussions about screening options, risk factors,
and treatment considerations for gastrointestinal bleeding and related
conditions. These programs provide healthcare providers with
tools and resources to support patient education, counseling, and follow-up
care for individuals undergoing screening and treatment for gastrointestinal
disorders. This factor will pace up the demand of the Global Gastrointestinal
Bleeding Treatment Market.
Technological Advancements
Endoscopic
imaging technologies, such as high-definition and narrow-band imaging, have
improved visualization of gastrointestinal lesions and bleeding sources. These
technologies enhance the ability of gastroenterologists to detect subtle
abnormalities and accurately localize bleeding sites during endoscopic
procedures. Endoscopic hemostatic techniques have evolved with the development
of various devices and methods for achieving hemostasis in gastrointestinal
bleeding. These include hemostatic clips, thermal coagulation probes, injection
therapy with sclerosants or hemostatic agents, and newer technologies like
over-the-scope clips (OTSC) and hemostatic powders. These techniques allow for
precise and effective control of bleeding lesions, reducing the need for
invasive surgical interventions. Capsule endoscopy involves the ingestion of a
small, wireless capsule camera that captures images of the gastrointestinal
tract as it passes through the digestive system. Capsule endoscopy is
particularly useful for evaluating obscure gastrointestinal bleeding, as it can
visualize areas of the small intestine that are inaccessible to traditional
endoscopic techniques. Double balloon enteroscopy enables deep intubation of
the small intestine using a specialized endoscope with an overtube and balloon
attachments. This technique allows for the visualization and treatment of
lesions in the small intestine, including sources of obscure gastrointestinal
bleeding.
Angiographic
embolization is a minimally invasive procedure used to control gastrointestinal
bleeding by selectively occluding blood vessels that supply bleeding lesions.
Advanced imaging modalities, such as digital subtraction angiography (DSA),
allow interventional radiologists to precisely identify and target bleeding
vessels, leading to successful hemostasis while preserving surrounding tissue. Radiofrequency
ablation is a technique that uses thermal energy to destroy abnormal tissue,
such as precancerous lesions or dysplastic tissue associated with Barrett's
esophagus. RFA can be used to treat gastrointestinal bleeding secondary to
conditions like Barrett's esophagus and certain types of precancerous lesions. Hemostatic
powders composed of biocompatible materials, such as hydrophilic polymers or
mineral particles, can be applied endoscopically to bleeding lesions to achieve
hemostasis. These powders adhere to the bleeding surface and promote clot
formation, providing an effective means of controlling gastrointestinal
bleeding, particularly in difficult-to-reach or high-risk areas. Wireless pH
monitoring systems enable ambulatory monitoring of esophageal pH levels to
evaluate gastroesophageal reflux disease (GERD) and assess the severity of
esophageal mucosal injury. These systems utilize wireless pH capsules placed in
the esophagus to record pH levels over a specified period, providing valuable
diagnostic information for the management of GERD-related complications,
including esophageal bleeding. This factor will accelerate the demand of the Global
Gastrointestinal Bleeding Treatment Market.
Download Free Sample Report
Key Market Challenges
High Cost of Treatment
Gastrointestinal
bleeding treatment often involves the use of advanced medical technology and
equipment, including endoscopes, imaging systems, hemostatic devices, and
surgical instruments. The high cost of acquiring, maintaining, and upgrading
these technologies contributes to the overall cost of treatment. Gastrointestinal
bleeding treatment may require the expertise of specialized healthcare
providers, including gastroenterologists, interventional radiologists, and
gastrointestinal surgeons. These specialists typically command higher fees for
their services, contributing to the overall cost of treatment. The diagnostic
workup for gastrointestinal bleeding may involve various imaging studies,
laboratory tests, and endoscopic procedures to identify the underlying cause
and location of bleeding.
These diagnostic procedures can incur substantial
costs, especially when multiple tests and imaging modalities are necessary to
achieve an accurate diagnosis. Therapeutic interventions for gastrointestinal
bleeding, such as endoscopic hemostasis, angiographic embolization, and
surgical procedures, can be costly due to the use of specialized equipment,
disposable supplies, anesthesia, and operating room expenses. The complexity
and duration of these interventions may further contribute to their cost. Pharmacological
treatments for gastrointestinal bleeding, including proton pump inhibitors
(PPIs), anticoagulants, and hemostatic agents, can be expensive, especially for
patients requiring long-term or combination therapy. The cost of medications
may vary based on factors such as brand name versus generic formulations,
dosage regimens, and insurance coverage.
Risk of Complications
Many
treatment modalities for gastrointestinal bleeding, such as endoscopic
hemostasis, angiographic embolization, and surgical interventions, are invasive
procedures that carry inherent risks of complications, including bleeding,
perforation, infection, and adverse reactions to anesthesia or contrast agents.
Patients with gastrointestinal bleeding often have underlying health
conditions, such as cardiovascular disease, liver cirrhosis, renal
insufficiency, or coagulopathies, which may increase the risk of complications
during treatment. Pre-existing comorbidities can complicate the management of
gastrointestinal bleeding and necessitate careful risk stratification and
treatment planning.
Pharmacological treatments for gastrointestinal bleeding,
including anticoagulants, antiplatelet agents, and nonsteroidal
anti-inflammatory drugs (NSAIDs), carry the risk of side effects such as
gastrointestinal ulcers, renal impairment, and increased bleeding risk. The use
of these medications in combination with other therapies for gastrointestinal
bleeding may heighten the risk of adverse events and treatment-related
complications. Individual patient factors, such as age, comorbidities,
nutritional status, medication history, and adherence to treatment regimens,
can influence the risk of complications during gastrointestinal bleeding
treatment. Elderly patients and those with multiple medical conditions may be
particularly vulnerable to treatment-related adverse events and may require
tailored management approaches to mitigate risks.
Key Market Trends
Growing Demand of Biologic
Therapies
Biologic
therapies offer targeted approaches to gastrointestinal bleeding treatment by
selectively inhibiting pro-inflammatory cytokines, immune mediators, and cell
signaling pathways involved in the pathophysiology of gastrointestinal
disorders. By modulating specific molecular targets, biologic agents can
attenuate inflammation, promote mucosal healing, and mitigate the risk of
gastrointestinal bleeding in conditions such as inflammatory bowel disease
(IBD) and autoimmune gastritis. Clinical trials and real-world studies have
demonstrated the efficacy and safety of biologic therapies in achieving and
maintaining disease remission, reducing disease activity, and preventing
disease complications in patients with gastrointestinal bleeding. Biologic
agents such as anti-tumor necrosis factor (TNF) antibodies (e.g., infliximab,
adalimumab) and anti-integrin antibodies (e.g., vedolizumab) have shown
favorable outcomes in inducing and sustaining clinical and endoscopic remission
in patients with IBD and reducing the risk of gastrointestinal bleeding-related
hospitalizations and surgeries.
Biologic therapies have the potential to modify
the natural history of gastrointestinal diseases by altering disease
progression, preventing tissue damage, and modulating immune responses
implicated in disease pathogenesis. By intervening early in the disease course,
biologic agents may reduce the risk of long-term complications, including
gastrointestinal bleeding, strictures, fistulas, and colorectal cancer, in
patients with chronic inflammatory conditions affecting the gastrointestinal
tract. The advent of personalized medicine approaches, including biomarker
profiling, genetic testing, and pharmacogenomics, enables tailored selection of
biologic therapies based on individual patient characteristics, disease
phenotype, and treatment response. Personalized treatment algorithms help
optimize therapeutic outcomes, minimize adverse effects, and enhance patient
adherence to biologic therapy regimens in the management of gastrointestinal
bleeding and related complications.
Segmental Insights
GI Tract Division Insights
The
Lower GI Tract segment is projected to experience significant dominance in the
Global Gastrointestinal Bleeding Treatment Market during the forecast period. Disorders
affecting the lower gastrointestinal (GI) tract, including the colon, rectum,
and anus, are common and can lead to gastrointestinal bleeding. Conditions such
as diverticulosis, colorectal cancer, inflammatory bowel disease (IBD), and
hemorrhoids contribute to the substantial burden of lower GI tract disorders
globally. As the incidence and prevalence of these conditions rise, there is a
greater demand for effective treatments to manage gastrointestinal bleeding
originating from the lower GI tract. Advances in diagnostic technologies, such
as colonoscopy, flexible sigmoidoscopy, and capsule endoscopy, have improved
the detection and localization of sources of lower GI bleeding.
These
technologies enable healthcare providers to accurately diagnose and assess the
severity of lower GI tract disorders, facilitating targeted treatment
interventions to control bleeding and prevent complications. Minimally invasive
treatment options for lower GI tract bleeding, including endoscopic therapies
such as thermal coagulation, injection therapy, and endoscopic clips, offer
effective alternatives to traditional surgical approaches. These minimally
invasive techniques are associated with reduced patient discomfort, shorter
hospital stays, and faster recovery times, driving their adoption for the
management of lower GI bleeding. The implementation of colorectal cancer
screening programs and initiatives aimed at early detection and prevention of
lower GI tract disorders has increased awareness and detection rates among
at-risk populations. Screening programs help identify individuals with
precancerous lesions or early-stage colorectal cancer, enabling timely
intervention to prevent disease progression and reduce the risk of
gastrointestinal bleeding-related complications.
End Users Insights
The
Hospital/Clinics segment is projected to experience significant growth in the
Global Gastrointestinal Bleeding Treatment Market during the forecast period. Hospitals
and clinics serve as primary points of access for patients seeking medical
care, including gastrointestinal bleeding treatment. As healthcare access
improves globally, more individuals are likely to visit hospitals and clinics
for diagnosis and treatment of gastrointestinal bleeding. Hospitals and clinics
typically have advanced medical infrastructure, including endoscopy suites,
interventional radiology facilities, and operating rooms equipped to perform
complex procedures to diagnose and treat gastrointestinal bleeding effectively.
The availability of such infrastructure enhances the capacity of hospitals and
clinics to manage a wide range of gastrointestinal bleeding cases.
Gastrointestinal
bleeding often requires a multidisciplinary approach involving
gastroenterologists, interventional radiologists, surgeons, and other
healthcare professionals. Hospitals and clinics provide an ideal setting for
collaboration among specialists from different disciplines to develop
comprehensive treatment plans tailored to individual patient needs. Many
hospitals and clinics offer specialized services dedicated to the diagnosis and
treatment of gastrointestinal disorders, including gastrointestinal bleeding.
These specialized centers often have dedicated teams of healthcare
professionals with expertise in managing various gastrointestinal conditions,
ensuring high-quality care and optimal patient outcomes.
Download Free Sample Report
Regional Insights
North
America emerged as the dominant region in the Global Gastrointestinal Bleeding
Treatment Market in 2023. North America boasts highly developed healthcare
infrastructure, including state-of-the-art hospitals, specialized treatment
centers, and advanced medical technology. These facilities enable healthcare
providers to offer a wide range of diagnostic and treatment options for
gastrointestinal bleeding, including endoscopic procedures, interventional
radiology, and surgical interventions. The region is at the forefront of
technological innovation in healthcare, with ongoing advancements in diagnostic
imaging, endoscopic devices, and therapeutic interventions for gastrointestinal
bleeding. These technological innovations improve the accuracy of diagnosis,
enhance treatment outcomes, and contribute to the overall quality of patient
care.
North America is home to a large pool of skilled healthcare
professionals, including gastroenterologists, interventional radiologists,
surgeons, and nurses, who specialize in the diagnosis and treatment of
gastrointestinal disorders. The expertise of these healthcare professionals
contributes to the delivery of high-quality care and the effective management
of gastrointestinal bleeding cases. The region benefits from robust investment
in research and development (R&D) initiatives aimed at advancing medical
knowledge, developing new treatment modalities, and improving patient outcomes
in gastrointestinal bleeding management. Academic institutions, healthcare
organizations, and industry stakeholders collaborate to drive innovation and
translate scientific discoveries into clinical practice.
Recent Developments
- In September 2023, Apollo Hospitals inaugurated an Advanced Centre for Gastro-Intestinal Bleed as part of its 40th-anniversary celebrations, aiming to address the needs of patients with GI-related issues and elevate its medical standards. Aligned with international standards, the center pledges to enhance patient outcomes by providing cutting-edge treatments. Staffed with proficient professionals and equipped with advanced facilities, the center ensures prompt diagnosis and top-notch care for various digestive disorders spanning from the esophagus to the biliary system.
Key Market Players
- Boston
Scientific Corporation
- Olympus Corporation
- CONMED Corporation
- Ovesco Endoscopy AG
- Erbe Elektromedizin GmbH
- Steris Plc
- US Medical Innovations, LLC.
- Pfizer Inc.
|
By
Product
|
By
GI Tract Division
|
By
End Users
|
By
Region
|
- Closure
Devices
- Endoscopic
Hemostatic Devices
- Others
|
- Upper
GI Tract
- Lower
GI Tract
|
- Hospital/Clinics
- Ambulatory
Surgical Centres
- Others
|
- North
America
- Europe
- Asia-Pacific
- South
America
- Middle
East & Africa
|
Report Scope:
In this report, the Global Gastrointestinal
Bleeding Treatment Market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
- Gastrointestinal Bleeding Treatment Market, By Product:
o Closure Devices
o Endoscopic Hemostatic Devices
§ Thermal Devices
§ Mechanical Devices
o Others
- Gastrointestinal Bleeding Treatment Market, By GI Tract Division:
o Upper GI Tract
o Lower GI Tract
- Gastrointestinal Bleeding Treatment Market, By End Users:
o Hospital/Clinics
o Ambulatory Surgical Centres
o Others
- Gastrointestinal Bleeding Treatment Market, By
Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ Germany
§ United Kingdom
§ France
§ Italy
§ Spain
o Asia-Pacific
§ China
§ Japan
§ India
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Gastrointestinal
Bleeding Treatment Market.
Available Customizations:
Global Gastrointestinal Bleeding Treatment market
report with the given market data, Tech Sci Research offers customizations
according to a company's specific needs. The following customization options
are available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Gastrointestinal Bleeding Treatment Market
is an upcoming report to be released soon. If you wish an early delivery of
this report or want to confirm the date of release, please contact us at [email protected]